ALX Oncology Holdings (ALXO)
(Real Time Quote from BATS)
$15.91 USD
+0.17 (1.08%)
Updated Apr 19, 2024 02:08 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Income Statements
Fiscal Year end for ALX Oncology Holdings Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 1 | 5 |
Cost Of Goods | 0 | 0 | 0 | 1 | 4 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 170 | 127 | 84 | 44 | 20 |
Income After Depreciation & Amortization | -170 | -127 | -84 | -44 | -19 |
Non-Operating Income | 11 | 4 | 0 | -1 | 0 |
Interest Expense | 2 | 0 | 0 | 1 | 0 |
Pretax Income | -161 | -123 | -83 | -46 | -19 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -161 | -123 | -83 | -46 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -161 | -123 | -83 | -46 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -176 | -128 | -84 | -43 | -19 |
Depreciation & Amortization (Cash Flow) | -5 | -1 | 0 | 1 | 0 |
Income After Depreciation & Amortization | -170 | -127 | -84 | -44 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 42.99 | 40.70 | 40.31 | 18.49 | NA |
Diluted EPS Before Non-Recurring Items | -3.74 | -3.03 | -2.07 | -2.37 | NA |
Diluted Net EPS (GAAP) | -3.74 | -3.03 | -2.07 | -2.76 | NA |
Fiscal Year end for ALX Oncology Holdings Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 48.02 | 53.28 | 36.78 | 32.20 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -48.02 | -53.28 | -36.78 | -32.20 |
Non-Operating Income | NA | 2.97 | 2.68 | 2.99 | 2.41 |
Interest Expense | NA | 0.42 | 0.39 | 0.37 | 0.39 |
Pretax Income | NA | -45.47 | -50.99 | -34.16 | -30.18 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -45.47 | -50.99 | -34.16 | -30.18 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -45.47 | -50.99 | -34.16 | -30.18 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 49.00 | 41.15 | 40.88 | 40.86 |
Diluted EPS Before Non-Recurring Items | NA | -0.93 | -1.24 | -0.84 | -0.58 |
Diluted Net EPS (GAAP) | NA | -0.92 | -1.24 | -0.84 | -0.74 |